CSL's Share Price Can Outperform on Results Beat

Dow Jones08-18

2331 GMT [Dow Jones]--Australian pharmaceutical company CSL's share price looks a good bet to outperform today, RBC Capital Markets says. CSL's FY26 underlying earnings and revenue beat expectations. "We think the market will particularly like the immunoglobulin performance with FY26 revenue growth of 4% year-over-year and 2H26 growth of 14% on-year," analyst Craig Wong-Pan says. CSL expects FY27 revenue to match the FY26 outcome. It also expects underlying profit growth of 5% when currency swings are stripped out. This implies an underlying net profit of US$2.93 billion, above consensus hopes of US$2.83 billion. "The stock has had a strong run into this result, however we expect the FY27 guidance beat to consensus and strong immunoglobulin performance in 2H26 to drive outperformance in the stock today," RBC says.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment